Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor Response-Reference-Cited by-同舟云学术

Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor Response

Published:2023-09 Issue:7 Volume: Page:
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precision Oncology

Author:

Moore Jay A.¹,Chen Kuei-Ting¹,Madison Russell¹^ORCID,Newberg Justin Y.¹,Fleischmann Zoe¹,Wang Shuoguo¹,Sharaf Radwa¹^ORCID,Murugesan Karthikeyan¹^ORCID,Fendler Bernard J.¹,Hughes Jason¹,Schrock Alexa B.¹^ORCID,Hegde Priti S.¹,Oxnard Geoffrey R.¹^ORCID,Fabrizio David¹^ORCID,Frampton Garrett M.¹^ORCID,Antonarakis Emmanuel S.²^ORCID,Sokol Ethan S.¹^ORCID,Jin Dexter X.¹^ORCID

Affiliation:

1. Foundation Medicine Inc, Cambridge, MA

2. University of Minnesota Masonic Cancer Center, Minneapolis, MN

Abstract

Analysis of 260K tumors IDs copy-number signatures and a HRD biomarker predictive of PARPi response.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.23.00093

Reference40 articles.